BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 6541693)

  • 1. Biological properties of human tissue-type plasminogen activator obtained by expression of recombinant DNA in mammalian cells.
    Collen D; Stassen JM; Marafino BJ; Builder S; De Cock F; Ogez J; Tajiri D; Pennica D; Bennett WF; Salwa J
    J Pharmacol Exp Ther; 1984 Oct; 231(1):146-52. PubMed ID: 6541693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological and thrombolytic properties of proenzyme and active forms of human urokinase--III. Thrombolytic properties of natural and recombinant urokinase in rabbits with experimental jugular vein thrombosis.
    Collen D; Stassen JM; Blaber M; Winkler M; Verstraete M
    Thromb Haemost; 1984 Aug; 52(1):27-30. PubMed ID: 6541817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
    Matsuo O; Rijken DC; Collen D
    Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase.
    Dewerchin M; Vandamme AM; Holvoet P; De Cock F; Lemmens G; Lijnen HR; Stassen JM; Collen D
    Thromb Haemost; 1992 Aug; 68(2):170-9. PubMed ID: 1412163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
    Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC
    Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic effect on thrombolysis of sequential infusion of tissue-type plasminogen activator (t-PA) single-chain urokinase-type plasminogen activator (scu-PA) and urokinase in the rabbit jugular vein thrombosis model.
    Collen D; Stassen JM; De Cock F
    Thromb Haemost; 1987 Oct; 58(3):943-6. PubMed ID: 3124288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancement of clot lysis in vitro and in vivo with a bispecific monoclonal antibody directed against human fibrin and against urokinase-type plasminogen activator.
    Kurokawa T; Iwasa S; Kakinuma A; Stassen JM; Lijnen HR; Collen D
    Thromb Haemost; 1991 Dec; 66(6):684-93. PubMed ID: 1796414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
    Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
    Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological and thrombolytic properties of proenzyme and active forms of human urokinase--I. Fibrinolytic and fibrinogenolytic properties in human plasma in vitro of urokinases obtained from human urine or by recombinant DNA technology.
    Zamarron C; Lijnen HR; Van Hoef B; Collen D
    Thromb Haemost; 1984 Aug; 52(1):19-23. PubMed ID: 6495259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological and thrombolytic properties of proenzyme and active forms of human urokinase--IV. Variability in fibrinolytic response of plasma of several mammalian species.
    Lijnen HR; De Wreede K; Demarsin E; Collen D
    Thromb Haemost; 1984 Aug; 52(1):31-3. PubMed ID: 6495261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small animal thrombosis models for the evaluation of thrombolytic agents.
    Stassen JM; Lijnen HR; Kieckens L; Collen D
    Circulation; 1991 Jun; 83(6 Suppl):IV65-72. PubMed ID: 2040073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombolytic properties in a rabbit jugular vein thrombosis model of a tissue-type plasminogen activator mutant lacking the growth factor--and kringle one-domains.
    Emeis JJ; Verheijen JH
    Arzneimittelforschung; 1992 Mar; 42(3):358-62. PubMed ID: 1497699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular mechanisms of fibrinolysis and their application to fibrin-specific thrombolytic therapy.
    Collen D
    J Cell Biochem; 1987 Feb; 33(2):77-86. PubMed ID: 3553213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
    Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
    Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical and biological properties of a recombinant tissue-type plasminogen activator derived from the rat JMI-229 cell line.
    Lijnen HR; Webb PD; Van Hoef B; De Cock F; Stassen JM; Prior SD; Collen D
    Thromb Haemost; 1992 Feb; 67(2):239-47. PubMed ID: 1621244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potentiation by Lys-plasminogen of clot lysis by single or two chain urokinase-type plasminogen activator or tissue-type plasminogen activator.
    Watahiki Y; Scully MF; Ellis V; Kakkar VV
    Thromb Haemost; 1989 Jun; 61(3):502-6. PubMed ID: 2508259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro studies on the fibrinolytic, thrombolytic and fibrinogenolytic properties of a tissue plasminogen activator from guinea pig keratocytes.
    Electricwala A; Ling RJ; Sutton PM; Griffiths B; Riley PA; Atkinson T
    Thromb Haemost; 1985 Apr; 53(2):200-3. PubMed ID: 4040659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of epithelial tissue plasminogen activator as a thrombolytic agent in a rabbit model of venous thrombosis.
    Electricwala A; Emeis JJ; Atkinson T
    J Pharmacol Exp Ther; 1986 Jul; 238(1):254-8. PubMed ID: 2425075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of standard heparin and a low molecular weight heparin on thrombolytic and fibrinolytic activity of single-chain urokinase plasminogen activator in vitro.
    Lourenço DM; Dosne AM; Kher A; Samama M
    Thromb Haemost; 1989 Nov; 62(3):923-6. PubMed ID: 2556812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibrin specific thrombolysis by two-chain urokinase-type plasminogen activator cleaved after arginine 156 by thrombin.
    Abercrombie DM; Buchinski B; Salvato KA; Vovis GF; Stump DC; Broeze RJ
    Thromb Haemost; 1990 Nov; 64(3):426-32. PubMed ID: 2128973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.